Previous 10 |
The Portfolio Barometer Using an inductive portfolio model approach that goes where the types of returns in the market are strongest, I monitor different fundamental, value, momentum, forensic, and anomaly portfolios from financial research to create a portfolio barometer. This article conti...
BOSTON, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other diseases, announced today that Pet...
The first patient has been dosed in a Phase 1 dose-escalation study evaluating Pieris Pharmaceuticals' ( PIRS +2.9% ) PRS-343, combined with Roche's Tecentriq (atezolizumab), in patients with advanced/metastatic HER2-positive solid tumors. More news on: Pieris Pharmaceuticals, Inc., ...
BOSTON, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for cancer, respiratory and other diseases, announced today that...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies Combined company is expected to have approximately $80.5 millio...